Cubist Systematic Strategies, LLC Ultragenyx Pharmaceutical Inc. Transaction History

Cubist Systematic Strategies, LLC

$19.3 Billion
Q3 2025

A detailed history of Cubist Systematic Strategies, LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 172,674 shares of RARE stock, worth $5.71 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

172,674

Previous 85,282 102.47%

Holding current value

$5.71 Million

Previous $3.1 Million 67.55%

% of portfolio

0.03%

Previous 0.02%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$26.31 - $41.44 $2.3 Million - $3.62 Million	87,392 Added 102.47%	172,674 $5.19 Million
Q2 2025 Aug 14, 2025	SELL	$31.06 - $39.3 $1.13 Million - $1.42 Million	-36,228 Reduced 29.81%	85,282 $3.1 Million
Q1 2025 May 15, 2025	BUY	$36.21 - $45.78 $4.4 Million - $5.56 Million	121,510 New	121,510 $4.4 Million
Q3 2024 Nov 14, 2024	BUY	$40.21 - $59.36 $7.38 Million - $10.9 Million	183,490 New	183,490 $10.2 Million
Q1 2024 May 15, 2024	BUY	$43.02 - $53.69 $973,585 - $1.22 Million	22,631 New	22,631 $1.06 Million

Q3 2023 Nov 14, 2023	SELL	$34.92 - $46.66 $4.65 Million - $6.21 Million	-133,156 Reduced 82.03%	29,178 $1.04 Million
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $2.64 Million - $3.68 Million	-70,634 Reduced 30.32%	162,334 $7.49 Million
Q1 2023 May 15, 2023	BUY	$36.99 - $48.71 $287,375 - $378,427	7,769 Added 3.45%	232,968 $9.34 Million
Q4 2022 Feb 14, 2023	SELL	$33.72 - $46.33 $653,493 - $897,875	-19,380 Reduced 7.92%	225,199 $10.4 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $9.24 Million - $15.3 Million	231,245 Added 1734.25%	244,579 $10.1 Million
Q2 2022 Aug 15, 2022	SELL	$45.8 - $85.4 $1.23 Million - $2.29 Million	-26,819 Reduced 66.79%	13,334 $796,000
Q1 2022 May 16, 2022	BUY	$62.2 - $84.4 $2.05 Million - $2.78 Million	32,913 Added 454.6%	40,153 $2.92 Million
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $2.37 Million - $2.83 Million	-32,208 Reduced 81.65%	7,240 $609,000
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $11.2 Million - $14.7 Million	-143,360 Reduced 78.42%	39,448 $3.56 Million
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $13.7 Million - $17.2 Million	148,274 Added 429.36%	182,808 $17.4 Million
Q1 2021 May 17, 2021	SELL	$106.9 - $167.73 $4.14 Million - $6.49 Million	-38,715 Reduced 52.85%	34,534 $3.93 Million
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $3.32 Million - $6.97 Million	39,317 Added 115.87%	73,249 $10.1 Million
Q3 2020 Nov 16, 2020	BUY	$72.98 - $90.0 $2.48 Million - $3.05 Million	33,932 New	33,932 $2.79 Million
Q2 2020 Aug 14, 2020	SELL	$46.91 - $78.22 $509,583 - $849,703	-10,863 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$33.8 - $62.9 $307,343 - $571,949	-9,093 Reduced 45.57%	10,863 $483,000
Q4 2019 Feb 14, 2020	SELL	$36.08 - $45.83 $625,843 - $794,967	-17,346 Reduced 46.5%	19,956 $852,000
Q3 2019 Nov 14, 2019	BUY	$42.5 - $63.11 $1.46 Million - $2.17 Million	34,396 Added 1183.62%	37,302 $1.6 Million
Q2 2019 Aug 14, 2019	BUY	$54.93 - $74.36 $159,626 - $216,090	2,906 New	2,906 $185,000
Q1 2019 May 15, 2019	SELL	$39.87 - $69.36 $794,569 - $1.38 Million	-19,929 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$38.89 - $77.3 $455,363 - $905,105	11,709 Added 142.45%	19,929 $867,000
Q3 2018 Nov 14, 2018	BUY	$71.81 - $90.15 $590,278 - $741,033	8,220 New	8,220 $628,000
Q2 2018 Aug 14, 2018	SELL	$48.54 - $85.31 $125,815 - $221,123	-2,592 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$44.33 - $58.52 $141,191 - $186,386	-3,185 Reduced 55.13%	2,592 $132,000
Q4 2017 Feb 14, 2018	SELL	$43.54 - $57.32 $152,825 - $201,193	-3,510 Reduced 37.79%	5,777 $268,000
Q3 2017 Nov 14, 2017	BUY	$49.79 - $66.32 $462,399 - $615,913	9,287	9,287 $495,000

Others Institutions Holding RARE

# of Institutions

348

Shares Held

88.2M

Call Options Held

2.19M

Put Options Held

1.04M

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.32B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account

Cubist Systematic Strategies, LLC Ultragenyx Pharmaceutical Inc. Transaction History